Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Contract manufacturing organizations often assume cyclodextrin dimerization behaves like conventional small-molecule synthesis, proposing process modifications that fail in practice. Specialized carbohydrate chemistry behaves unpredictably, requiring therapeutic sponsors to temper vendor confidence and actively guide external manufacturing teams.

Related Insights

The standard CDMO business model, which charges for fermentation time, rewards maximizing equipment utilization rather than process innovation. This creates a misalignment with clients who want faster, more efficient processes. An alternative model aligns CDMO revenue with process improvements, not process duration.

David Craig advises against fully entrusting manufacturing to a CDMO. He keeps a Chief Technical Officer in-house to manage the project plan's minutiae. This internal oversight prevents missed timelines and manages rate-limiting steps, which often derail virtual programs relying solely on external partners for execution.

A CDMO that promises a problem-free process without asking tough questions is a red flag. The best partners are those who challenge your assumptions early. This indicates they are engaged and invested in success, rather than being overconfident or apathetic.

Synthesizing a therapeutic molecule is insufficient for commercial success; the actual challenge is making medicine possible through rigorous regulatory and quality compliance. Thousands of small biotechs focus capital strictly on research pipelines and lack the capital to build expensive manufacturing facilities. Specialized CDMO partners provide the compliant infrastructure, specialized people, and end-to-end quality systems needed to advance molecules through clinical phases to approval.

Companies often prioritize small gains in a drug's activity (PK/PD data) during candidate selection, while ignoring manufacturability. This can lead to selecting a molecule that is extremely difficult or costly to produce, a problem that a slightly less active but more manufacturable alternative would have avoided.

The standard practice is to optimize for productivity (titer) first, then correct for quality (glycosylation) later. This is reactive and inefficient. Successful teams integrate glycan analysis into their very first screening experiments, making informed, real-time trade-offs between productivity and quality attributes.

Although cyclodextrin building blocks are biological products generated by microbial enzymes, decades of commercial use in foods and solvents matured their extraction. This industrial scale allows modern therapeutics to source ultrapure starting materials cheaply at scale without investing in complex upstream fermentation development.

A process that seems simple in a development lab is often not viable in a strict GMP manufacturing environment. To create truly manufacturable therapies, process development scientists need direct, hands-on exposure to GMP constraints and workflows to avoid significant rework and delays.

Companies often mistakenly expect their CDMO to fill strategic gaps. A CDMO's role is to execute the plan provided. Handing over an incomplete process is a 'wish,' not a tech transfer, and forces them to improvise in ways that may not align with your regulatory or commercial goals.

Two critical mistakes derail glycoengineering efforts. First, delaying analytical feedback on glycan profiles turns optimization into blind guesswork. Second, failing to test interactions with other process parameters like pH and temperature early on creates a process that is not robust and is prone to failure at scale.